Zebi Naz, MD
Family Medicine · Paw Paw, MINPI 1114128501
Payments from drug & device makers
Across 116 payments — averaging $18.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$243
- Pfizer$170
- Boehringer Ingelheim$131
- Merck$129
- Amgen$129
- Novartis$118
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,16999%
- Education$131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 12 | $243 |
| Pfizer | 10 | $170 |
| Boehringer Ingelheim | 7 | $131 |
| Merck | 6 | $129 |
| Amgen(2 entities) | 7 | $129 |
| Novartis | 6 | $118 |
| AbbVie | 5 | $107 |
| AstraZeneca | 7 | $101 |
| GSK | 5 | $83 |
| Lilly USA, LLC | 5 | $81 |
| Otsuka America Pharmaceutical, Inc. | 3 | $79 |
| Dexcom, Inc. | 3 | $70 |
| Daiichi Sankyo Inc. | 3 | $68 |
| Johnson & Johnson | 4 | $65 |
| Exact Sciences | 3 | $56 |
| Astellas Pharma US Inc | 3 | $55 |
| Bayer | 3 | $47 |
| Abbott | 2 | $45 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $43 |
| Inspire Medical Systems, Inc. | 1 | $41 |
| Shire North American Group Inc | 2 | $34 |
| Axsome Therapeutics, Inc. | 1 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $30 |
| Sanofi Pasteur Inc. | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Biomarin Pharmaceutical Inc. | 1 | $21 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Viiv Healthcare Company | 1 | $17 |
| Phadia US Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| AMAG Pharmaceuticals, Inc. | 1 | $13 |
| Gilead | 1 | $12 |
How this compares
$2,183 in reported general payments places this provider in the 80th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 113 | $126,539 |
| JardianceEmpagliflozin | 77 | $87,535 |
| EliquisApixaban | 57 | $70,397 |
| MounjaroTirzepatide | 48 | $50,910 |
| TrulicityDulaglutide | 42 | $46,482 |
| RybelsusSemaglutide | 19 | $38,629 |
| FarxigaDapagliflozin Propanediol | 27 | $23,853 |
| LinzessLinaclotide | 18 | $19,245 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 67 | $10,879 |
| Atorvastatin Calcium | 512 | $7,756 |
| CreonLipase/Protease/Amylase | 15 | $6,844 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $5,834 |
| Ropinirole ErRopinirole Hcl | 21 | $4,732 |
| Omeprazole | 251 | $3,645 |
| DuleraMometasone/Formoterol | 11 | $3,627 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $243 | $165,167132 claims |
| Lilly USA, LLCMounjaro, Trulicity | $81 | $97,39190 claims |
| Boehringer IngelheimJardiance | $131 | $87,53577 claims |
| PfizerEliquis | $170 | $70,39757 claims |
| AbbVieLinzess, Creon | $107 | $26,08933 claims |
| AstraZenecaFarxiga | $101 | $23,85327 claims |
| GSKIncruse Ellipta | $83 | $5,83417 claims |
| MerckDulera | $129 | $3,62711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Paw Paw
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.